TOP

Press Releases

You can read it in the journals and newspapers, or you can read it here first. Please check back frequently to see where the future is headed, compliments of Sequenom.

July 2014

Jul 22, 2014 SAN DIEGO, July 22, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin reporting on the presence of three additional clinically relevant subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS) for its MaterniT21™ PLUS laboratory-developed test. The microdeletions added include 11q deletion (Jacobsen... Read more
New Data Supporting the Clinical Validity of Sequenom Laboratories' Noninvasive Prenatal Tests Presented at the 18th International Conference on Prenatal Diagnosis and Therapy Jul 21, 2014 SAN DIEGO, July 21, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch  the VisibiliT™ laboratory-developed test in international markets. The... Read more
Jul 15, 2014 SAN DIEGO, July 15, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the second quarter of 2014 after closing of the NASDAQ Global Market on Tuesday, July 29, 2014. A conference call hosted by William Welch, Chief Executive Officer, and other members of senior management will take place on the same day at 5:00 p.m. EDT (2:00 p.m. PDT) and will be webcast... Read more

June 2014

Jun 19, 2014 SOPHIA ANTIPOLIS, France, and SAN DIEGO, June 19, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes... Read more
Jun 16, 2014 MADISON, N.J. and SAN DIEGO, June 16, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21™ PLUS laboratory-developed test (LDT). Using a maternal blood sample, the noninvasive prenatal test (NIPT)... Read more
Jun 16, 2014 SAN DIEGO, June 16, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, announced today that it has received premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx™ System.  The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated for... Read more

Pages